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temperature of 9 h (6.35-12 h). Combined therapy with MTH and angioplasty
was performed in 26.5% of cases. In multivariate analysis, only 5 parameters
were significantly associated with a better outcome, absence of dyslipidemia
(OR= 4.34[1.3-17.2]), age<70 years (OR =8.57[2.07-45.27]), no flow duration
<10 min (16.57[2.6-143.7]), adrenalin dose <6 mg (OR=13.34 [3.54-64.08])
and shockable rhythm (OR=19.45 [4.43-114.52]). We used these parameters
weighted according to their odds ratio to define a new score, called DAANS
score (Dyslipidemia (1), Age>70 (2), Adrenalin dose>6 mg (3), No flow dura-
tion >10 min (4) and a non Shockable rhythm (5)) to assess the mortality risk
during the initial management of patients victims of OHCA. Retrospectively
in this study, a DAANS score >7 was predictor of a 100% mortality.
Conclusion: Pre-hospital classical criterias of poor prognosis after cardiac
arrest could be integrated in a simple initial prognostic score (DAANS score)
that could help guiding the optimal management (coronarography, MTH, pro-
longed resuscitation) for victims of OHCA.
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Objectives: To compare the feasibility, safety and outcome of IMPELLA
Recover LP2.5 cardiac assistance and intra aortic balloon pump (IABP) in
patients with post-cardiac arrest shock.
Background: Even after successful resuscitation, the in-hospital survival
rate of post-cardiac arrest patients remains very low. Recently, a LV percuta-
neous mechanical assistance using the IMPELLA Recover LP2.5 has been
proposed in order to improve the circulatory abnormalities and to allow fur-
ther neurological evaluation.
Methods: Retrospective single center registry performed by the interven-
tional cardiology and intensive care departments. All survivors of out-of-hos-
pital cardiac arrest with patent post-resuscitation shock or predictive factors for
the occurrence of shock assisted by either IMPELLA or intra aortic balloon
pump (IABP) device immediately after the coronary angiogram were included.
Results: 78 post-cardiac arrest patients were assisted (35 by IMPELLA
and 43 by IABP). Most of the patients had an acute coronary syndrome as
cause of OHCA. Median “no flow” and median “low flow” were similar as
hemodynamic parameters at admission. The feasibility (97%) of IMPELLA
implantation was very satisfying. At 28 days, the survival rate without
sequellae was 23.0% in the IMPELLA group and 29.5% in the IABP group
(p=0.61). Post-cardiac arrest shock was the leading cause of death in the
IMPELLA group (n= 21). Vascular complication were observed equally in
both groups (3 vs 2, p=0.9). Serious bleeding complications requiring tranfu-
sion occurred in 26% of IMPELLA patients vs 9% of IABP patients (p=0.06)
and bleeding requiring increase in vasopressor occurred in 9% of patients in
both groups.
Conclusion: Emergent LV assistance by the IMPELLA LP 2.5 is feasible
in patients with post-resuscitation shock. The rate of complication did not
differ substantially in the two groups. These encouraging findings must be
confirmed in a larger clinical study.
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Introduction: Iatrogenic events were defined as adverse drug reactions or
complications induced by non-drug interventions, such as cardiac devices or
stimulation techniques. Iatrogenic complications (IC) are associated with pro-
longed hospitalization and higher in-hospital mortality. In the real world IC
are mainly evaluated during hospital stay. The present study focused on
admission in a coronary care unit (CCU) for an adverse effect and we aimed:
a) to evaluate the prevalence and the characteristics of these admissions and
the types of iatrogeny; b) and to assess the in-hospital mortality.
Methods: From April 2008 to May 2012, all the consecutive admissions
caused IC at the CCU were prospectively studied and classified in 2 groups:
1) pharmacological adverse effect (antiarrythmics, anticoagulant, and anti-
platelets), 2) non pharmacological adverse effect (pace maker, Automatic
Implantable Cardiovertor Defibrillator, radiofrequency, stent, cardiac surgery).
Results: On 7550 admissions, 302 (4%) IC as admission cause were
included in the study. Most patients with IC were male (58%) with a mean age
at 71±15 years. The in-hospital mortality of IC group was similar to those in
the general population (8% for both). The following table presents the results
of the 2 groups (N (%) or mean±SD).
Conclusion: This preliminary work shows the high frequency of iatrogenic
events as a cause of CCU. Work will be necessary to better understand the
causes of iatrogeny in order to limit this pathology.
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Background: The rational and the benefit of load expansion is controver-
sial in acute pulmonary embolism (PE). Diuretic may reduce RV preload and
improve hemodynamic status. The present study reported the safety of furo-
semide in normotensive acute PE with oligo-anuria.
Methods and Results: We prospectively included 68 consecutive normo-
tensive patients (systolic blood pressure ≥90 mmHg) admitted for acute PE
with oligoanuria and RV dilation. RV dilation was defined by a right and left
ventricular diameter ratio >0.6. Overall, 29 patients were treated by a repeated
bolus of furosemide (83±84 mg, range 40 to 160 mg), while 39 patients
received isotonic saline solution (1.6±0.8 L, range, 0.5 to 4,0 L). Patients
treated by furosemide and fluid expansion had similar severity of hypoxemia
but the furosemide group had lower admission blood pressure (119±21 mmHg
vs. 132±18 mmHg, P=0.007) and greater shock index defined as heart rate and
blood pressure ratio (0.81±0.23 vs. 0.69±0.18, P=0.02). Despite these differ-
ences, only the furosemide group had decrease shock index (0.81±0.23 vs.
0.62±0.17, P<0.0001) with improved systolic blood pressure (119±21 mmHg
vs. 133 ±18 mmHg, P<0.001), heart rate (93±19 bpm vs. 81±18 bpm,
P<0.001), and creatinin level. Finally, more patients were weaned in oxygen
at 24 hours (39% vs. 19%) and in-hospital survival without death and PE-
related shock was similar between the two groups (93% vs. 95%). 
Conclusions: In normotensive PE with oligoanuria and RV dilatation,
diuretic can be safely delivered to improve systolic blood pressure and oxy-
genation.
 (%) Men Age (y) Hospital death
Total 302 178(58%) 71±15 25(8%)
Non pharmacological 
adverse effect
161 (53%) 79(49%) 75±14 13(8.1%)
Pharmacological adverse 
effect
141 (47%) 99(70%) 67±17 12(8.5%)
p p<0.001 p<0.001 p=0.891
